eXoZymes

Historical price data

eXoZymes is redefining complex molecule discovery and manufacturing by combining AI-driven enzyme design with cell-free bioprocessing. The company's platform accelerates evolution, designing stable enzymes in weeks to produce rare or economically inaccessible compounds with high purity and scalability. With a pipeline spanning metabolic health, non-intoxicating cannabinoids, and high-value fragrances, eXoZymes targets capital-light growth across pharmaceutical, wellness, and industrial markets, validated by recent successful pilot-scale runs with partners like Cayman Chemical.

AI-enhanced, cell-free biomanufacturing platform that designs and engineers isolated enzymes ('exozymes') to catalyze the sustainable production of small molecules outside of living cells, enabling precise control and scalable synthesis.

Competes with cell-based synthetic biology firms (e.g., Ginkgo Bioworks) by avoiding cellular scaling issues, and with enzyme engineering companies (e.g., Codexis) by specializing in AI-driven design for cell-free systems. Its main differentiation is the integrated AI + cell-free bioprocessing platform focused on manufacturability from discovery.